
On Wednesday, Novo Nordisk surprised the market when it released its financial report for the first half of 2022 – the evening before it was scheduled to do so.
The Danish pharmaceutical giant disappointed on the bottom line compared to analysts’ high expectations, but the report still included a guidance upgrade for the full year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app